Malignant pleural mesothelioma incidence and survival in the Republic of Ireland 1994-2009

Cancer Epidemiology

Volumn 38, Issue 1, 2014, Pages 35-41

  Jennings, Cormac J ^a   Walsh, Paul M ^b   Deady, Sandra ^b   Harvey, Brian J ^a   Thomas, Warren ^a  

^a BEAUMONT HOSPITAL   (Ireland)

^b NATIONAL CANCER REGISTRY IRELAND   (Ireland)

Author keywords

Asbestos; Incidence; Ireland; Mesothelioma; Occupational health; Survival

Indexed keywords

ASBESTOS; INCIDENCE; IRELAND; MESOTHELIOMA; OCCUPATIONAL HEALTH; SURVIVAL;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ASBESTOS; ENVIRONMENTAL EXPOSURE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; IRELAND; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM STAGING; PLEURAL NEOPLASMS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK FACTORS; SURVIVAL RATE; YOUNG ADULT;

EID: 84894238344     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2013.12.002     Document Type: Article

References (32)

1. Bolton R.E., Davis J.M., Donaldson K., Wright A. Variations in the carcinogenicity of mineral fibres. Ann Occup Hyg 1982, 26:569-582.
2. Kabir Z., Clancy L. Mesothelioma trends in the Republic of Ireland: an epidemiologic study in the context of the causal pathway. Ir Med J 2003, 96:299-302.
3. Siesling S., van der Zwan J.M., Izarzugaza I., Jaal J., Treasure T., Foschi R., et al. Rare thoracic cancers, including peritoneum mesothelioma. Eur J Cancer 2012, 48:949-960.
4. Neumann V., Rutten A., Scharmach M., Muller K.M., Fischer M. Factors influencing long-term survival in mesothelioma patients - results of the German mesothelioma register. Int Arch Occup Environ Health 2004, 77:191-199.
5. Christensen B.C., Godleski J.J., Roelofs C.R., Longacker J.L., Bueno R., Sugarbaker D.J., et al. Asbestos burden predicts survival in pleural mesothelioma. Environ Health Perspect 2008, 116:723-726.
6. Jennings C.J., O'Grady A., Cummins R., Murer B., Al-Alawi M., Madden S.F., et al. Sustained expression of steroid receptor coactivator SRC-2/TIF-2 is associated with better prognosis in malignant pleural mesothelioma. J Thorac Oncol 2012, 7:243-248.
7. Pinton G., Brunelli E., Murer B., Puntoni R., Puntoni M., Fennell D.A., et al. Estrogen receptor-beta affects the prognosis of human malignant mesothelioma. Cancer Res 2009, 69:4598-4604.
8. Doll R., Cook P. Summarizing indices for comparison of cancer incidence data. Int J Cancer 1967, 2:269-279.
9. Gordon I.O., Sitterding S., Mackinnon A.C., Husain A.N. Update in neoplastic lung diseases and mesothelioma. Arch Pathol Lab Med 2009, 133:1106-1115.
10. Aoe K., Amatya V.J., Fujimoto N., Ohnuma K., Hosono O., Hiraki A., et al. CD26 overexpression is associated with prolonged survival and enhanced chemosensitivity in malignant pleural mesothelioma. Clin Cancer Res 2012, 18:1447-1456.
11. Marinaccio A., Binazzi A., Cauzillo G., Cavone D., Zotti R.D., Ferrante P., et al. Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register. Eur J Cancer 2007, 43:2722-2728.
12. Bianchi C., Bianchi T. Malignant mesothelioma: global incidence and relationship with asbestos. Ind Health 2007, 45:379-387.
13. Virta R.L. Worldwide asbestos supply and consumption trends from 1900 through 2003 2006, US Geological Survey, Reston, VA. Interior Dot (Ed.).
14. Rake C., Gilham C., Hatch J., Darnton A., Hodgson J., Peto J. Occupational, domestic and environmental mesothelioma risks in the British population: a case-control study. Br J Cancer 2009, 100:1175-1183.
15. McDonald J.C., McDonald A.D. Chrysotile, tremolite and carcinogenicity. Ann Occup Hyg 1997, 41:699-705.
16. Jung J.I., Kim H.H., Park S.H., Song S.W., Chung M.H., Kim H.S., et al. Thoracic manifestations of breast cancer and its therapy. Radiographics 2004, 24:1269-1285.
17. Sahn S.A. Pleural diseases related to metastatic malignancies. Eur Respir J 1997, 10:1907-1913.
18. van der Waals F.W. Differences in leading causes of death, hospitalization and general practice visits among Dutch women and men. Women Health 1991, 17:101-123.
19. Cancer services in Ireland: a national strategy 1996, Department of Health and Children, Dublin.
20. Law M.R., Hodson M.E., Heard B.E. Malignant mesothelioma of the pleura: relation between histological type and clinical behaviour. Thorax 1982, 37:810-815.
21. Schramm A., Opitz I., Thies S., Seifert B., Moch H., Weder W., et al. Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma. Eur J Cardiothorac Surg 2010, 37:566-572.
22. Van Gelder T., Damhuis R.A., Hoogsteden H.C. Prognostic factors and survival in malignant pleural mesothelioma. Eur Respir J 1994, 7:1035-1038.
23. Bolukbas S., Manegold C., Eberlein M., Bergmann T., Fisseler-Eckhoff A., Schirren J. Survival after trimodality therapy for malignant pleural mesothelioma: radical pleurectomy, chemotherapy with cisplatin/pemetrexed and radiotherapy. Lung Cancer 2011, 71:75-81.
24. Riaz S.P., Coupland V.H., Luchtenborg M., Peake M.D., Moller H. Mesothelioma incidence projections in South East England. Eur Respir J 2012, 40:965-968.
25. Delgermaa V., Takahashi K., Park E.K., Le G.V., Hara T., Sorahan T. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ 2011, 89(716-24). 24A-C.
26. Le Stang N., Belot A., Gilg Soit Ilg A., Rolland P., Astoul P., Bara S., et al. Evolution of pleural cancers and malignant pleural mesothelioma incidence in France between 1980 and 2005. Int J Cancer 2010, 126:232-238.
27. Burdorf A., Dahhan M., Swuste P. Occupational characteristics of cases with asbestos-related diseases in The Netherlands. Ann Occup Hyg 2003, 47:485-492.
28. McElvenny D.M., Darnton A.J., Price M.J., Hodgson J.T. Mesothelioma mortality in Great Britain from 1968 to 2001. Occup Med (Lond) 2005, 55:79-87.
29. Chapman A., Mulrennan S., Ladd B., Muers M.F. Population based epidemiology and prognosis of mesothelioma in Leeds, UK. Thorax 2008, 63:435-439.
30. Vogelzang N.J., Rusthoven J.J., Symanowski J., Denham C., Kaukel E., Ruffie P., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21:2636-2644.
31. Kanazawa N., Ioka A., Tsukuma H., Ajiki W., Oshima A. Incidence and survival of mesothelioma in Osaka, Japan. Jpn J Clin Oncol 2006, 36:254-257.
32. Carbone M., Yang H. Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma. Clin Cancer Res 2012, 18:598-604.